Pancreas, Insulin, and Diabetes: Physiology and Pathophysiology

The pancreas is a dual-function organ: exocrine (digestive enzymes) and endocrine (islets of Langerhans). The endocrine pancreas regulates glucose homeostasis via hormone secretion.

Islet Cell Types and Hormones

Cell TypeHormonePrimary Action
β-cells (65–80%)InsulinLowers blood glucose: promotes cellular uptake (GLUT4), glycogen synthesis, lipogenesis, protein synthesis; inhibits gluconeogenesis, glycogenolysis, lipolysis
α-cells (15–20%)GlucagonRaises blood glucose: stimulates glycogenolysis, gluconeogenesis, ketogenesis
δ-cells (3–10%)SomatostatinInhibits insulin, glucagon, growth hormone, GI secretion
PP cells (1–2%)Pancreatic polypeptideRegulates pancreatic exocrine secretion, gastric emptying, appetite
ε-cells (<1%)GhrelinStimulates appetite, GH release

Insulin Secretion Dynamics

  • Trigger: Glucose enters β-cell via GLUT2 → glycolysis → ↑ATP/ADP → closes KATP channels → depolarization → voltage-gated Ca²⁺ influx → insulin granule exocytosis.
  • Phases: First phase (rapid, 0–10 min, stored granules); second phase (sustained, newly synthesized).
  • Modulators: Incretins (GLP-1, GIP) amplify; somatostatin, sympathetic (α2-adrenergic) inhibit.

Diabetes Pathophysiology

Type 1 (Autoimmune)

T-cell mediated β-cell destruction → absolute insulin deficiency. Requires exogenous insulin. Onset typically childhood/adolescence but can occur at any age.

Type 2 (Insulin Resistance + Relative Deficiency)

Peripheral insulin resistance (muscle, liver, adipose) + progressive β-cell failure. Risk factors: genetics, obesity, sedentary lifestyle, aging, ethnicity. Initially compensated by hyperinsulinemia; later decompensation → hyperglycemia.

Other Types

  • Gestational (pregnancy-induced insulin resistance)
  • MODY (monogenic β-cell dysfunction)
  • Pancreatogenic (Type 3c: chronic pancreatitis, cystic fibrosis, hemochromatosis)

Therapeutic Targets

Insulin replacement, sensitizers (metformin, TZDs), secretagogues (sulfonylureas, GLP-1 RAs, DPP-4 inhibitors), SGLT2 inhibitors (renal glucose excretion), amylin analogs, immunotherapy (teplizumab for T1D prevention).

Diabetes - Related Articles